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Progression free survival 14.5 months 42 months 9 months
Overall survival 19.5 months 44 months 19 months
Alive NED 7 5 2
Distal relapse (systemic) 7 1 6
Distal relapse (CNS) 3 1 2
Local relapse 3 3 0
Died (unrelated cause) 2 1 1
Mediastinal LN positive 
at surgery 5 1 4
Lehigh Valley Health Network, Allentown, Pennsylvania
Neo-adjuvant Chemotherapy and Radiation Therapy in Patients with Stage IIIA (N2) Non-Small Cell 
Lung Cancer (NSCLC): A Retrospective Analysis with Lessons Learned

















				 	 -	 57.6	years	(19-79)
•		Gender
				 	 -	 13	male,	13	female
•		Pathology
				 	 -	 Adenocarcinoma	-	10/25	
	 	 	 -	 Squamous	Cell	Carcinoma	-	13/25
•		PET/CT	scan	positive	with	pathological	confirmation	
	 	 	 -	 10/26	(38%)
•	PET/CT	scan	positive	only	





	 	 	 -	 	Medical	oncologist
	 	 	 -	 	Radiation	oncologist	
•		Patients	selected	up-front	for	trimodality	therapy	(prior	to	initiation	of	
treatment)
	 	 	 -	 Stage	IIIA	(T1-3	N2	M0)	NSCLC
	 	 	 -	 	Non-bulky	N2	disease	(<	3cm)
	 	 	 -	 	Good	performance	status	(ECOG	0-1)











	 	 	 -	 	Paclitaxel	50mg/m2	+	Carboplatin	
AUC	2	weekly	(n	=	15)
	 	 	 -	 Vinorelbine	25mg/m2	d1,	8,	15	
					 											Paclitaxel	140mg/m2	by	continuous
																		24-hour	infusion	d1	
	 	 	 							Carboplatin	AUC	5	d2				(n=6)
		 	 	 -	 	Paclitaxel	175mg/m2	+	carboplatin	
AUC	6	q3wks	(n	=	4)
	 	 	 -	 	Etoposide	50mg/m2	d	1-5	+	Cisplatin	
50mg/m2	d1	and	8			(n	=	1)
•		Radiation	Therapy
	 	 	 -	 	4500	–	5040	cGy	(concomitant	with	
chemotherapy)
•		Surgery
	 	 	 -	 	Pneumonectomy	(n	=	7)
	 	 	 -	 	Lobectomy	/	bilobectomy	(n	=	16)
Treatment:
	 	 	 -	 	Thoracic	surgeon	
	 	 	 -	 	Pulmonologist
	 	 	 -	 	Adenosquamous	1/26

























26 patien ts com p le ted
neoad juvant rad ia tion
and chem othe rapy
• 2 patien ts progressed fo llow ing
neoad juvant therapy
• 1 patien t had unexpected p leura l
d isease and surgery was aborted
• 23 patien ts com ple ted pu lm onary
resection
– 16 lobectom y/b ilobectom y
– 7 pneum onectom y
1 patien t lost to
fo llow -up after com ple ting
a ll treatm ent
22 patien ts inc luded in
curren t ana lys is
p = 0.068
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